Medication burden in bipolar disorder: A chart review of patients at psychiatric hospital admission

Psychiatry Research

Volumn 216, Issue 1, 2014, Pages 24-30

  Weinstock, Lauren M ^a   Gaudiano, Brandon A ^a   Epstein Lubow, Gary ^a   Tezanos, Katherine ^a   Celis deHoyos, Cintly E ^a   Miller, Ivan W ^a  

^a BUTLER HOSPITAL   (United States)

Author keywords

Antidepressants; Benzodiazepines; Bipolar depression; Demography; Mood stabilizers; Polypharmacy; Psychopharmacology

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CENTRAL STIMULANT AGENT; LITHIUM; PSYCHOTROPIC AGENT; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR;

ADULT; ANXIETY DISORDER; ARTICLE; BIPOLAR DISORDER; COMORBIDITY; DEPRESSION; DRUG USE; FEMALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; POLYPHARMACY; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEX DIFFERENCE; SUICIDE ATTEMPT; ADOLESCENT; AGED; ANXIETY; COMPLICATION; COST OF ILLNESS; EVALUATION STUDY; MENTAL HOSPITAL; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANXIETY; BIPOLAR DISORDER; COST OF ILLNESS; DEPRESSION; FEMALE; HOSPITALIZATION; HOSPITALS, PSYCHIATRIC; HUMANS; MALE; MIDDLE AGED; POLYPHARMACY; PSYCHOTROPIC DRUGS; RETROSPECTIVE STUDIES; SEX FACTORS; SUICIDE, ATTEMPTED; YOUNG ADULT;

EID: 84895876484     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2014.01.038     Document Type: Article

References (44)

1. American Psychiatric Association Practice Guidelines for Treatment of Patients With Bipolar Disorder - Revision 2002, American Psychiatric Association, Washington, DC.
2. Baldessarini R.J., Leahy L., Arcona S., Gause D., Zhang W., Hennen J. Patterns of psychotropic drug prescription for U.S. patients with diagnoses of bipolar disorders. Psychiatric Services 2007, 58:85-91.
3. Bates J.A., Whitehead R., Bolge S.C., Kim E. Correlates of medication adherence among patients with bipolar disorder: results of the bipolar evaluation of satisfaction and tolerability (BEST) study: a nationwide cross-sectional survey. Primary Care Companion to the Journal of Clinical Psychiatry 2010, 12. pii: PCC.09m00883. 10.4088/PCC.09m00883yel.
4. Bjerrum L., Sogaard J., Hallas J., Kragstrup J. Polypharmacy: correlations with sex, age and drug regimen. A prescription database study. European Journal of Clinical Pharmacology 1998, 54:197-202.
5. Blanco C., Laje G., Olfson M., Marcus S.C., Pincus H.A. Trends in the treatment of bipolar disorder by outpatient psychiatrists. American Journal of Psychiatry 2002, 159:1005-1010.
6. Copeland L.A., Zeber J.E., Salloum I.M., Pincus H.A., Fine M.J., Kilbourne A.M. Treatment adherence and illness insight in veterans with bipolar disorder. Journal of Nervous and Mental Disease 2008, 196:16-21.
7. Dennehy E.B., Suppes T., Rush A.J., Miller A.L., Trivedi M.H., Crismon M.L., Carmody T.J., Kashner T.M. Does provider adherence to a treatment guideline change clinical outcomes for patients with bipolar disorder? Results from the Texas Medication Algorithm Project. Psychological Medicine 2005, 35:1695-1706.
8. Frye M.A., Ketter T.A., Leverich G.S., Huggins T., Lantz C., Denicoff K.D., Post R.M. The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study. Journal of Clinical Psychiatry 2000, 61:9-15.
9. Gaudiano B.A., Weinstock L.M., Miller I.W. Improving treatment adherence in bipolar disorder: a review of current psychosocial treatment efficacy and recommendations for future treatment development. Behavior Modififcation 2008, 32:267-301.
10. Goldberg J.F., Brooks J.O., Kurita K., Hoblyn J.C., Ghaemi S.N., Perlis R.H., Miklowitz D.J., Ketter T.A., Sachs G.S., Thase M.E. Depressive illness burden associated with complex polypharmacy in patients with bipolar disorder: findings from the STEP-BD. Journal of Clinical Psychiatry 2009, 70:155-162.
11. Gören J.L., Tewksbury A. Drug interactions and polypharmacy. Polypharmacy in Psychiatry Practice 2013, 1:45-74.
12. Huxley N., Baldessarini R.J. Disability and its treatment in bipolar disorder patients. Bipolar Disorders 2007, 9:183-196.
13. Judd L.L., Akiskal H.S., Schettler P.J., Coryell W., Endicott J., Maser J.D., Solomon D.A., Leon A.C., Keller M.B. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Archives of General Psychiatry 2003, 60:261-269.
14. Judd L.L., Akiskal H.S., Schettler P.J., Endicott J., Maser J., Solomon D.A., Leon A.C., Rice J.A., Keller M.B. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Archives of General Psychiatry 2002, 59:530-537.
15. Judd L.L., Schettler P.J., Akiskal H.S., Maser J., Coryell W., Solomon D., Endicott J., Keller M. Long-term symptomatic status of bipolar I vs. bipolar II disorders. International Journal of Neuropsychopharmacology 2003, 6:127-137.
16. Judd L.L., Schettler P.J., Solomon D.A., Maser J.D., Coryell W., Endicott J., Akiskal H.S. Psychosocial disability and work role function compared across the long-term course of bipolar I, bipolar II and unipolar major depressive disorders. Journal of Affective Disorders 2008, 108:49-58.
17. Kemp D.E., Gao K., Chan P.K., Ganocy S.J., Findling R.L., Calabrese J.R. Medical comorbidity in bipolar disorder: relationship between illnesses of the endocrine/metabolic system and treatment outcome. Bipolar Disorders 2010, 12:404-413.
18. Ketter T.A. Nosology, diagnostic challenges, and unmet needs in managing bipolar disorder. Journal of Clinical Psychiatry 2010, 71:e27.
19. Kingsbury S.J., Yi D., Simpson G.M. Psychopharmacology: rational and irrational polypharmacy. Psychiatric Services 2001, 52:1033-1036.
20. Krishnan K.R. Psychiatric and medical comorbidities of bipolar disorder. Psychosomatic Medicine 2005, 67:1-8.
21. Kupfer D.J. The increasing medical burden in bipolar disorder. Journal of the American Medical Association 2005, 293:2528-2530.
22. Levine J., Chengappa K.N., Brar J.S., Gershon S., Yablonsky E., Stapf D., Kupfer D.J. Psychotropic drug prescription patterns among patients with bipolar I disorder. Bipolar Disorders 2000, 2:120-130.
23. Lim P.Z., Tunis S.L., Edell W.S., Jensik S.E., Tohen M. Medication prescribing patterns for patients with bipolar I disorder in hospital settings: adherence to published practice guidelines. Bipolar Disorders 2001, 3:165-173.
24. Lin D., Mok H., Yatham L.N. Polytherapy in bipolar disorder. CNS Drugs 2006, 20:29-42.
25. McIntyre R. Bipolar disorder and ADHD: clinical concerns. CNS Spectrums 2009, 14:8-9.
26. Misawa F., Shimizu K., Fujii Y., Miyata R., Koshiishi F., Kobayashi M., Shida H., Oguchi Y., Okumuera Y., Ito H., Kayama M., Kashima H. Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects?: a cross-sectional study. BMC Psychiatry 2011, 11:118.
27. Mojtabai R., Olfson M. National trends in psychotropic medication polypharmacy in office-based psychiatry. Archives of General Psychiatry 2010, 67:26-36.
28. Newcomer J.W. Medical risk in patients with bipolar disorder and schizophrenia. Journal of Clinical Psychiatry 2006, 67:25-30.
29. Oliver M.I., Pearson N., Coe N., Gunnell D. Help-seeking behaviour in men and women with common mental health problems: cross-sectional study. British Journal of Psychiatry 2005, 186:297-301.
30. Post R.M. The case for polypharmacy in the treatment of bipolar disorder. Psychiatric Times 2007, 24:1-8.
31. Post R.M., Denicoff K.D., Leverich G.S., Altshuler L.L., Frye M.A., Suppes T.M., Rush A.J., Keck P.E., McElroy S.L., Luckenbaugh D.H., Pollio C., Kupka R., Nolen W.A. Morbidity in 258 bipolar outpatients followed for 1 year with daily prospective ratings on the NIMH life chart method. Journal of Clinical Psychiatry 2003, 64:680-690.
32. Sachs G.S., Nierenberg A.A., Calabrese J.R., Marangell L.B., Wisniewski S.R., Gyulai L., Friedman E.S., Bowden C.L., Fosse M.D., Ostacher M.J., Ketter T.A., Patel J., Hauser P., Rapport D., Martinez J.M., Allen M.H., Miklowitz D.J., Otto M.W., Dennehy E.B., Thase M.E. Effectiveness of adjunctive antidepressant treatment for bipolar depression. New England Journal of Medicine 2007, 356:1711-1722.
33. Sachs, G.S., Peters, A.T., Sylvia, L., Grunze, H. Polypharmacy and bipolar disorder: what's personality got to do with it? International Journal of Neuropsychopharmacology, in press. http://dx.doi.org/10.1017/S1461145713000953.
34. Solomon D.A., Keitner G.I., Miller I.W., Shea M.T., Keller M.B. Course of illness and maintenance treatments for patients with bipolar disorder. Journal of Clinical Psychiatry 1995, 56:5-13.
35. Solomon D.A., Keitner G.I., Ryan C.E., Miller I.W. Polypharmacy in bipolar I disorder. Psychopharmacology Bulletin 1996, 32:579-587.
36. Stawicki S.P., Gerlach A.T. Polypharmacy and medication errors: stop, listen, look, and analyze. OPUS 12 Scientist 2009, 3:6-10.
37. Unutzer J., Simon G., Pabiniak C., Bond K., Katon W. The use of administrative data to assess quality of care for bipolar disorder in a large staff model HMO. General Hospital Psychiatry 2000, 22:1-10.
38. van Winkel R., De Hert M., Van Eyck D., Hanssens L., Wampers M., Scheen A., Peuskens J. Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder. Bipolar Disorders 2008, 10:342-348.
39. Velligan D.I., Weiden P.J., Sajatovic M., Scott J., Carpenter D., Ross R., Docherty J.P. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. Journal of Clinical Psychiatry 2009, 70:1-46.
40. Weinstock L.M., Strong D., Uebelacker L.A., Miller I.W. Differential item functioning of DSM-IV depressive symptoms in individuals with a history of mania versus those without: an item response theory analysis. Bipolar Disorders 2009, 11:289-297.
41. Weinstock L.M., Strong D., Uebelacker L.A., Miller I.W. DSM-IV depressive symptom expression among individuals with a history of hypomania: a comparison to those with or without a history of mania. Journal of Psychiatric Research 2010, 44:979-985.
42. Werder S.F., Preskorn S.H. Managing polypharmacy: walking the fine line between help and harm. Current Psychiatry 2003, 2:24-36.
43. Yatham L.N., Kennedy S.H., O'Donovan C., Parikh S., MacQueen G., McIntyre R., Sharma V., Silverstone P., Alda M., Baruch P., Beaulieu S., Daigneault A., Milev R., Young L.T., Ravindran A., Schaffer A., Connolly M., Gorman C.P. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disorders 2005, 7:5-69.
44. Yatham L.N., Kennedy S.H., Schaffer A., Parikh S.V., Beaulieu S., O'Donovan C., McQueen C., McIntyre R.S., Sharma V., Ravindran A., Young L.T., Young A.H., Alda M., Milev R., Vieta E., Calabrese J.R., Berk M., Ha K., Kapczinski F. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disorders 2009, 11:225-255.